Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Argus Health
Johnson and Johnson
Fish and Richardson
US Army
Accenture
QuintilesIMS
Federal Trade Commission
Healthtrust
Chubb

Generated: October 20, 2017

DrugPatentWatch Database Preview

Flutemetamol f-18 - Generic Drug Details

« Back to Dashboard

What are the generic sources for flutemetamol f-18 and what is the scope of flutemetamol f-18 patent protection?

Flutemetamol f-18
is the generic ingredient in one branded drug marketed by Ge Healthcare and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Flutemetamol f-18 has seventy-six patent family members in twenty-three countries and eighteen supplementary protection certificates in twelve countries.

One supplier is listed for this compound.

Summary for Generic Name: flutemetamol f-18

US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list1
Clinical Trials: see list18
Patent Applications: see list14
Drug Prices:see low prices
DailyMed Link:flutemetamol f-18 at DailyMed

Pharmacology for Ingredient: flutemetamol f-18

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-002Oct 25, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Ge Healthcare
VIZAMYL
flutemetamol f-18
INJECTABLE;INTRAVENOUS203137-001Oct 25, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: flutemetamol f-18

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,854,920Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition► Subscribe
8,911,707Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition► Subscribe
9,134,328Methods of using benzothiazole derivative compounds and compositions► Subscribe
8,404,213Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: flutemetamol f-18

Country Document Number Estimated Expiration
Israel203316► Subscribe
Japan5022554► Subscribe
Hong Kong1146725► Subscribe
Brazil0113470► Subscribe
New Zealand583616► Subscribe
Australia2008292201► Subscribe
Norway2015005► Subscribe
Spain2536449► Subscribe
Luxembourg92634► Subscribe
European Patent Office2182988► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FLUTEMETAMOL F-18

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015Austria► SubscribePRODUCT NAME: (18F) - FLUTEMETAMOL; REGISTRATION NO/DATE: EU/1/14/941 (MITTEILUNG) 20140826
90009-5Sweden► SubscribePRODUCT NAME: FLUTEMETAMOL (18F); REG. NO/DATE: EU/1/14/941 20140826
C0006France► SubscribePRODUCT NAME: FLUTEMETAMOL (18 F); REGISTRATION NO/DATE: EU/1/14/941 20140822
3 5003-2015Slovakia► SubscribePRODUCT NAME: FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822
2015 00009Denmark► SubscribePRODUCT NAME: FLUTEMETAMOL (18F); REG. NO/DATE: EU/1/14/941 20140822
0150004 00139Estonia► SubscribePRODUCT NAME: FLUTEMETAMOOL (18F);REG NO/DATE: EU/1/14/941 26.08.2014
634Luxembourg► SubscribePRODUCT NAME: FLUTEMETAMOL (18F) ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (VIZAMYL). FIRST REGISTRATION: 20140826
2015000017Germany► SubscribePRODUCT NAME: FLUTEMETAMOL (18F) IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/14/941 20140822
15006Norway► SubscribePRODUCT NAME: VIZAMYL; REG. NO/DATE: EU/1/14/941 20140822
2015000016Germany► SubscribePRODUCT NAME: FLUTEMETAMOL (18F) ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ, HYDRAT ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/14/941 20140822
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Baxter
Julphar
Johnson and Johnson
Fuji
Farmers Insurance
Citi
Express Scripts
AstraZeneca
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot